Sorrento, NantWorks commit $20mm to new immunotherapies JV; commitments later enhanced
Executive Summary
Sorrento Therapeutics Inc. and NantWorks LLC founder Dr. Patrick Soon-Shiong have agreed to together invest $20mm in a new joint venture, to be named The Immunotherapy Antibody JV, which will operate as an independent entity.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice